PENN-DIABEX

**PENN-DIABEX** is an investigational oral polyherbal antidiabetic formulation developed at Government College University Faisalabad. It contains extracts of *Opuntia ficus-indica* fruit, *Syzygium cumini* leaves, *Rhus coriaria* fruit, *Coffea arabica* fruit, and *Eclipta alba* whole plant. In a high-fat-diet plus streptozotocin-induced rat model of type 2 diabetes, the formulation reduced fasting blood glucose and HbA1c and improved lipid and selected liver-function measures versus untreated diabetic controls. Its proposed activity is inhibition of carbohydrate- and lipid-digesting enzymes, including alpha-amylase, alpha-glucosidase, and pancreatic lipase, thereby potentially delaying nutrient absorption and reducing hyperglycemia. PENN-DIABEX remains a preclinical formulation; the cited study recommends clinical evaluation before human use. A Pakistan patent application was filed on August 3, 2023.

Other names

PENN-DIABEX